agree. I’m big on looking at comparable trials to see how recruitment went as that’s often a good guide to the scale of the challenge . Take MPACT panc cancer trial I referred to before (gemcitabine + abraxane) . The published study says it took about 3 years with 150 sites to get 860 patients. That’s about 2 patients per site per year. Unless you think there’s a reason why ACCENT can substantially outperform MPACT , then I’d be using that estimate as a guide.
If that plays out here, with 11 sites, then could take at least a year to get this 26….
agree. I’m big on looking at comparable trials to see how...
Add ATX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.1¢ |
Change
-0.001(0.82%) |
Mkt cap ! $16.43M | |||
| Open | High | Low | Value | Volume |
| 6.1¢ | 6.2¢ | 6.0¢ | $21.91K | 360.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5 | 6.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.1¢ | 114727 | 1 |
View Market Depth
| Last trade - 15.57pm 16/05/2024 (20 minute delay) ? |
|
|||||
|
Last
6.1¢ |
Change
-0.001 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 6.1¢ | 6.2¢ | 6.1¢ | 30520 | ||
| Last updated 15.48pm 16/05/2024 ? | |||||
| ATX (ASX) Chart |